{
    "nctId": "NCT00107016",
    "briefTitle": "Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal Women",
    "officialTitle": "A Phase 2, Double-blind, Randomized, Placebo-controlled, Multi-center Study Assessing the Value of Adding Everolimus to Letrozole as Preoperative Therapy of Primary Breast Cancer in Postmenopausal Women",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Neoplasm",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 267,
    "primaryOutcomeMeasure": "To assess the added efficacy obtained by combining RAD001 and letrozole as preoperative therapy for four months in hormone-receptor positive breast cancer in postmenopausal women",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically-confirmed diagnosis of invasive breast cancer, previously untreated\n* Patients must be postmenopausal\n* Candidates for mastectomy or breast-conserving surgery\n* Primary tumor of above 2 cm diameter, measured by imaging\n* Clinical Stage M0\n* WHO performance status \u22641\n* Adequate bone marrow, liver, and renal function\n\nExclusion Criteria:\n\n* Multicentric invasive tumors\n* Bilateral or inflammatory breast cancer\n* Receiving concomitant anti-cancer treatments such as chemotherapy\n* Patients with an uncontrolled infection\n* Patients with other concurrent severe and/or uncontrolled medical disease\n\nAdditional protocol-defined inclusion/exclusion criteria may apply.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}